CISATRACURIUM BESYLATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for cisatracurium besylate and what is the scope of freedom to operate?
Cisatracurium besylate
is the generic ingredient in four branded drugs marketed by Accord Hlthcare, Caplin, Eugia Pharma, Fresenius Kabi Usa, Hainan Poly, Hengrui Pharma, Hikma, Hospira, Meitheal, Piramal, Piramal Critical, Sagent Pharms Inc, Sandoz Inc, Somerset, Zydus Pharms, Somerset Theraps Llc, and Abbvie, and is included in twenty-nine NDAs. Additional information is available in the individual branded drug profile pages.There are nine drug master file entries for cisatracurium besylate. Sixteen suppliers are listed for this compound.
Summary for CISATRACURIUM BESYLATE
US Patents: | 0 |
Tradenames: | 4 |
Applicants: | 17 |
NDAs: | 29 |
Drug Master File Entries: | 9 |
Finished Product Suppliers / Packagers: | 16 |
Raw Ingredient (Bulk) Api Vendors: | 63 |
Clinical Trials: | 12 |
Patent Applications: | 1,228 |
Drug Prices: | Drug price trends for CISATRACURIUM BESYLATE |
What excipients (inactive ingredients) are in CISATRACURIUM BESYLATE? | CISATRACURIUM BESYLATE excipients list |
DailyMed Link: | CISATRACURIUM BESYLATE at DailyMed |
Recent Clinical Trials for CISATRACURIUM BESYLATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Second Affiliated Hospital of Nanchang University | Phase 4 |
Yichang Humanwell Pharmaceutical Co.,Ltd | Phase 4 |
Second Affiliated Hospital of Nanchang University | N/A |
Pharmacology for CISATRACURIUM BESYLATE
Drug Class | Nondepolarizing Neuromuscular Blocker |
Physiological Effect | Neuromuscular Nondepolarizing Blockade |
Anatomical Therapeutic Chemical (ATC) Classes for CISATRACURIUM BESYLATE
Paragraph IV (Patent) Challenges for CISATRACURIUM BESYLATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NIMBEX PRESERVATIVE FREE | Injection | cisatracurium besylate | 2 mg/mL, 10 mL vial | 020551 | 1 | 2009-08-12 |
NIMBEX PRESERVATIVE FREE | Injection | cisatracurium besylate | 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial | 020551 | 1 | 2009-08-04 |
US Patents and Regulatory Information for CISATRACURIUM BESYLATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospira | CISATRACURIUM BESYLATE | cisatracurium besylate | INJECTABLE;INJECTION | 203236-001 | Mar 30, 2018 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Abbvie | NIMBEX PRESERVATIVE FREE | cisatracurium besylate | INJECTABLE;INJECTION | 020551-002 | Dec 15, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Hengrui Pharma | CISATRACURIUM BESYLATE PRESERVATIVE FREE | cisatracurium besylate | INJECTABLE;INJECTION | 204960-001 | Jan 27, 2017 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CISATRACURIUM BESYLATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | NIMBEX | cisatracurium besylate | INJECTABLE;INJECTION | 020551-001 | Dec 15, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | NIMBEX PRESERVATIVE FREE | cisatracurium besylate | INJECTABLE;INJECTION | 020551-003 | Dec 15, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | NIMBEX PRESERVATIVE FREE | cisatracurium besylate | INJECTABLE;INJECTION | 020551-002 | Dec 15, 1995 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.